Kevin Li

Lepu Medical Technology (Beijing) Co., Ltd. was established in 1999. Lepu Medical is specialized in developing, manufacturing and distributing the high-tech medical devices and equipment. Today, Lepu Medical has grown into a global leading group company in the fields of cardiovascular interventions, structural heart diseases, neurointervention, cardiac rhythm management, anesthesia and critical care, in vitro diagnostics, ECG & patient monitoring, hemodialysis, orthopedics, skin care and general surgery. In 2009, Lepu Medical was successfully listed on ChiNext Shenzhen Stock Exchange market (stock code: 300003) with the market value of 10 billion USD. In 2022, Lepu Medical was listed on the SIX Swiss Exchange. Now Lepu Medical totally has 28 primary subsidiary companies worldwide. There are more than 234 products have received the CE certificates, and 34 products have got the FDA approvals. As the National Interventional Cardiology Medical Instruments & Engineering Technology Research Center, Lepu Medical Group’s top strategy is to build up a 4 in 1 platform includes medical device, pharmaceutical, Healthcare Service, Mobile Medical. Currently, Lepu Medical has established three overseas subsidiary companies in the Netherlands, Turkey and the United States, obtained local registrations in 40+ countries, and built sales and distribution channels in over 120+ countries and regions. Lepu Medical upholds “integrity, quality and scientific innovation” as its spirit, commitments to provide the best quality of products and services to satisfy the needs of healthcare professionals and patients.